Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics

Transgene Announces Upcoming Investor Meetings

PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.
December 15, 2022 GMT

STRASBOURG, France--(BUSINESS WIRE)--Dec 15, 2022--

Regulatory News:

TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in January and February 2023, as set out below.

Transgene will meet institutional investors at the 12 th Annual LifeSci Advisors Corporate Access Event and at BIO Partnering at JPM in San Francisco from January 9 to 12, 2023, in conjunction with the J.P. Morgan Healthcare conference.

The Company will also attend:

  • 26 th ODDO BHF Forum (virtual): January 9-10, 2023;
  • Invest Securities Biomed Forum: January 24, 2023;
  • Degroof Petercam’s Virtual Healthcare Conference: January 27, 2023;
  • BIO CEO & Investor Forum (New York): February 6-9, 2023.

About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac ® platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO™ platform).
With Transgene’s myvac ® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac ® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca.
Additional information about Transgene is available at:
Follow us on Twitter: @TransgeneSA

View source version on

CONTACT: Transgene:

Lucie Larguier

Director Corporate Communications & IR

+33 (0)3 88 27 91 04

investorrelations@transgene.frMedia: MEDiSTRAVA Consulting

David Dible/Sylvie Berrebi/George Underwood

+44 (0)203 928 6900



SOURCE: Transgene

Copyright Business Wire 2022.

PUB: 12/15/2022 11:45 AM/DISC: 12/15/2022 11:47 AM